Global Virome Project

Global Virome Project
Name	Global Virome Project
Type	International research initiative
Established	2018
Focus	Viral discovery, pathogen surveillance, pandemic prevention
Location	Global (headquarters: proposed)

Contents

Global Virome Project The Global Virome Project was an international initiative proposed to map the majority of zoonotic viruses in wildlife to improve global pandemic preparedness. Conceived by specialists affiliated with institutions such as the World Health Organization, Centers for Disease Control and Prevention, Wellcome Trust, Bill & Melinda Gates Foundation, and academic centers like Harvard University and Oxford University, the project sought to bridge gaps exposed by outbreaks like Ebola virus epidemic in West Africa (2014–2016), Zika virus epidemic, and the COVID-19 pandemic. Proponents argued that systematic viral discovery could inform strategies used by programs such as PREDICT (USAID), Global Influenza Surveillance and Response System, and initiatives led by the National Institutes of Health.

Background and Rationale

The proposal emerged amid mounting concern following high-profile crises including Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome, and the 2009 swine flu pandemic. Advocates referenced historical responses coordinated by organizations like the World Health Organization during the H1N1 2009 pandemic and surveillance networks exemplified by the Global Polio Eradication Initiative. Scientific rationale drew on virology breakthroughs at laboratories such as the Rockefeller University, Pasteur Institute, and Scripps Research Institute, and built on zoonotic research traditions from institutions including Smithsonian Institution and Royal Botanic Gardens, Kew. Funders and policymakers compared the project’s prospective value to landmark efforts like the Human Genome Project and collaborations exemplified by the Coalition for Epidemic Preparedness Innovations.

Primary aims included cataloging viral diversity in high-risk wildlife reservoirs — especially bats, rodents, and primates — across biodiversity hotspots like the Amazon Rainforest, Congo Basin, and Southeast Asian rain forests. Goals targeted improved early-warning capacity for pathogen emergence, enhancement of diagnostics used by laboratories such as National Institute of Allergy and Infectious Diseases, and data integration with public health entities like Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control. Scope encompassed genomic sequencing consistent with platforms developed by Illumina, Oxford Nanopore Technologies, and databases modeled on GenBank and the Global Initiative on Sharing All Influenza Data.

Planned methods combined field ecology techniques practiced at organizations like the Wildlife Conservation Society and the Zoological Society of London with high-throughput sequencing and bioinformatics pipelines inspired by work at Broad Institute and European Bioinformatics Institute. Sampling strategies emphasized host-targeted surveillance informed by ecological models from researchers at Stanford University and University of California, Berkeley. Laboratory workflows proposed biosafety standards referencing protocols from the Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control, and ethical oversight modeled on committees such as those at Wellcome Trust and national review boards like the National Institutes of Health Institutional Review Board.

The initiative envisioned collaborations among international agencies including the World Health Organization, financial backers like the Bill & Melinda Gates Foundation and Wellcome Trust, and academic partners such as Harvard University, University of Oxford, Imperial College London, and Johns Hopkins University. Implementation partners referenced conservation actors including the World Wildlife Fund, Conservation International, and regional research centers like the Institut Pasteur network and African Centres for Disease Control and Prevention. Proposed funding mechanisms were compared to models used by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Global Alliance for Vaccines and Immunization.

Pilot programs and precursor efforts, such as those by PREDICT (USAID) and studies conducted by teams at University of California, Davis and Duke University, yielded thousands of viral sequences expanding repositories like GenBank and informing risk frameworks used by National Institutes of Health. Findings highlighted viral diversity in genera associated with known zoonoses, influencing vaccine target prioritization in programs similar to Coalition for Epidemic Preparedness Innovations and diagnostic design at manufacturers like Roche Diagnostics. The research contributed to ecological understanding relevant to conservation actors such as BirdLife International and policy discussions at forums like the World Health Assembly.

Debate centered on data sharing norms akin to discussions at Global Initiative on Sharing All Influenza Data and benefit-sharing principles referenced in the Nagoya Protocol. Ethical concerns invoked standards upheld by institutional review boards of National Institutes of Health and guidance from organizations such as Wellcome Trust regarding equitable collaboration with researchers in low- and middle-income countries including institutions in Kenya, Peru, and Vietnam. Legal considerations involved biosafety regulation frameworks used by agencies like the European Centre for Disease Prevention and Control and export controls debated in contexts such as the Biological Weapons Convention review processes.

Critics compared the project's feasibility and cost to contested investments like the Large Hadron Collider and questioned risk assessments cited by commentators from think tanks such as Cato Institute and Chatham House. Concerns raised by scholars at institutions like Massachusetts Institute of Technology and University of Oxford included biosecurity risks, potential dual-use research issues debated in Asilomar Conference on Recombinant DNA-influenced literature, and opportunity costs relative to strengthening health systems highlighted by advocates at Médecins Sans Frontières and The Lancet. Policy debates featured parliaments and agencies in countries including United States Congress and European Parliament.

Category:Virology